Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …

For decades, HER2-positive breast cancer was associated with poor outcomes and higher
mortality rates than other breast cancer subtypes. However, the advent of Trastuzumab …

Significant advances have occurred in the treatment of human epidermal growth factor
receptor 2 (HER2)‐positive breast cancer that have changed its natural history. The addition …

Simple Summary HER2-positive breast cancer (BC), which accounts for~ 20% of BC, is one
of the more aggressive and has the worst overall survival rate among them. These patients …

Background Human epidermal growth factor receptor 2 (HER2) is overexpresed in 15–20%
of all breast cancers. Treatment with trastuzumab has led to an improved outcome and …

HER2-positive breast cancer is an aggressive subtype identified in the 1980s. The
development of therapies targeting the HER2 has improved outcomes. The current standard …

Advances in HER2-targeted therapies have improved the survival of patients with HER2-
positive breast cancer. The standard-of-care treatment for localized disease has been …

Targeting human epidermal growth factor receptor 2 (HER2) during or in sequence with
chemotherapy improves overall survival in metastatic and early HER2-overexpressing …

The advent of HER2-directed therapies has significantly improved the outlook for patients
with HER2-positive early stage breast cancer. However, a significant proportion of these …

Abstract Approximately 15–20% of all breast cancers are human epidermal growth factor
receptor 2 (HER2) positive, with clinical studies having validated the HER2 receptor tyrosine …